Electrochemotherapy of cutaneous metastases in malignant melanoma.
Electrochemotherapy is a new anticancer therapy in which transient permeabilization of cells by an electric field induces a significant increase in the bleomycin concentration and toxicity in tumour cells. We report a clinical study of electrochemotherapy in malignant melanoma. The main issues addressed were the effect of the size of the nodules, the optimization of the electrical parameters, and posttreatment clinical observations. Four patients were enrolled in the study. They received a 10 mg/m2 dose of bleomycin administered intravenously, followed by short, intense electric pulses applied directly to the skin at the tumour sites. Antitumour effects were obtained, especially in the smallest nodules. Objective responses were obtained in more than 90% of the 55 nodules treated, with a complete response rate of 9%. All patients tolerated the treatment well. No residual effects from the electric pulses were observed, even when a high number of pulses were required or when two consecutive treatments were applied. These results are encouraging and the study should be continued.
Rols
M P
MP
Institut de Pharmacologie et de Biologie Structurale du CNRS (UPR 9062), Toulouse, France. rols@ipbs.fr
Bachaud
J M
JM
Giraud
P
P
Chevreau
C
C
Roché
H
H
Teissié
J
J
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004599:Electric Stimulation Therapy; D018274:Electroporation; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000556:secondary / Q000628:therapy*
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin